Results 71 to 80 of about 231,281 (308)
Potential therapeutic drug candidates against SARS-CoV-2 (COVID‐19) through molecular docking: A review [PDF]
Health Science Monitor, 2022 The severe acute respiratory syndrome coronavirus 2 (known as COVID-19), initially appeared in the Wuhan city of China in December 2019, has become a current medical issue around the world.
Aynaz Nourani +2 more
doaj
Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review
Respiratory Research, 2021 Background The COVID-19 pandemic has affected the world extraordinarily. This disease has a potential to cause a significantly severe course of disease leading to respiratory complications, multiple organ failure and possibly death.
Alina Kröker, Madara Tirzīte
doaj +1 more source
Prevention and treatment of ventilator-associated pneumonia in COVID-19
Frontiers in Pharmacology, 2022 Ventilator-associated pneumonia (VAP) is the most common acquired infection in the intensive care unit. Recent studies showed that the critical COVID-19 patients with invasive mechanical ventilation have a high risk of developing VAP, which result in a ...
Jiayi Deng +4 more
doaj +1 more source
, 2023 Early treatment with antivirals against SARS-CoV-2 infection can prevent the onset of severe COVID-19 in fragile and immunocompromised patients. In this real-life, prospective, observational study, we evaluated efficacy and safety of a 3-day early ...
Alessia Sardanelli +9 more
core +1 more source
Design and analysis strategies for robust microbiome ageing research
FEBS Letters, EarlyView.The gut microbiome changes with age and associates with age‐related morbidity and mortality, establishing it as a potential biomarker and intervention target for ageing. Realising this potential requires methodological rigour, yet distinguishing biological signals from methodological artefacts remains challenging across cohorts. This review provides an
Mark Olenik +5 more
wiley +1 more source
Tackling Immune Pathogenesis of COVID-19 through Molecular Pharmaceutics
Pharmaceutics, 2021 An increasing number of clinical studies worldwide are investigating the repurposing of antiviral, immune-modulatory, and anti-inflammatory agents to face the coronavirus disease-19 (COVID-19) pandemic.
Matteo Puccetti +3 more
doaj +1 more source
Drug treatment for Covid-19 - three years later
Infectious Diseases Now, 2023 There has been a profusion of trials for SARS CoV2 drugs. A review dating from May 2020 listed 115 medicines, most of which previously existed, having been investigated since the onset of the pandemic. Over an exceedingly short lapse of time, the perspective of the arrival of a new antiviral treatment specifically targeting COVID-19 appeared highly ...
openaire +2 more sources
FEBS Open Bio, EarlyView.Chemotherapy side effects significantly impact cancer survivors' quality of life. Using protein levels in blood samples from breast cancer patients before and after 12 weeks of taxane treatment, we detected treatment‐dependent changes in calcium signaling and aging pathways associated with cancer recurrence.
Saira Munshani +6 more
wiley +1 more source
Alcohol and other drug treatment services in Australia annual report.
, 2021 Alcohol and other drug (AOD) treatment agencies across Australia provide a range of services and support to people receiving treatment for their own drug use, as well as for their families and friends.
core
Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives
Frontiers in Pharmacology, 2020 The COVID-19 pandemic represents an unprecedented challenge for the researchers to offer safe, tolerable, and effective treatment strategies for its causative agent known as SARS-CoV-2.
Chandan Sarkar +9 more
doaj +1 more source